A novel binding pocket of cyclin-dependent kinase 2

Proteins: Structure, Function and Bioinformatics

Volumn 74, Issue 1, 2009, Pages 122-132

  Chen, Hao ^a   Van Duyne, Rachel ^b   Zhang, Naigong ^a,d   Kashanchi, Fatah ^a,b,c   Zeng, Chen ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c J CRAIG VENTER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Binding pocket; Cell cycle; Computer docking simulations; Cyclin dependent kinase; Peptide inhibitor

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; CDK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; COMPUTER SIMULATION; ENZYME INHIBITOR INTERACTION; ENZYME SUBSTRATE COMPLEX; INHIBITION KINETICS; MOLECULAR DOCKING; PRIORITY JOURNAL; CHEMISTRY; DRUG ANTAGONISM; HUMAN; METABOLISM; PROTEIN BINDING;

EUKARYOTA;

BINDING SITES; COMPUTER SIMULATION; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; HUMANS; PROTEIN BINDING;

EID: 58949085676     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22136     Document Type: Article

References (24)

1. Morgan DO. The cell cycle: principles of control. London: New Science Press; 2007. 297 p.
2. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995;376:313-320.
3. Aleem E, Berthet C, Kaldis P. Cdk2 as a master of S phase entry: fact or fake? Cell Cycle 2004;3:35-37.
4. Fischer PM. The use of CDK inhibitors in oncology: a pharmaceutical perspective. Cell Cycle 2004;3:742-746.
5. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-1783.
6. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005;14:457-477.
7. Bogoyevitch MA, Barr RK, Ketterman AJ. Peptide inhibitors of protein kinases-discovery, characterisation and use. Biochim Biophys Acta 2005;1754:79-99.
8. Mclnnes C, Andrews MJ, Zheleva DI, Lane DP, Fischer PM. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents 2003;3:57-69.
9. McInnes C, Fischer PM. Strategies for the design of potent and selective kinase inhibitors. Curr Pharm Des 2005;11:1845-1863.
10. Gondeau C, Gerbal-Chaloin S, Bello P, Aldrian-Herrada G, Morris MC, Divita G. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J Biol Chem 2005;280: 13793-13800.
11. Lu Y, Nikolovska-Coleska Z, Fang X, Gao W, Shangary S, Qiu S, Qin D, Wang S. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J Med Chem 2006;49:3759-3762.
12. Agbottah E, Zhang N, Dadgar S, Pumfery A, Wade JD, Zeng C, Kashanchi F. Inhibition of HIV-1 virus replication using small soluble Tat peptides. Virology 2006;345:373-389.
13. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-1662.
14. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:27-38.
15. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995;8:127-134.
16. Gao Y, Wang R, Lai L. Structure-based method for analyzing protein-protein interfaces. J Mol Model 2004;10:44-54.
17. Venkatachalam CM, Jiang X, Oldfield T, Waldman M. Ligand-Fit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 2003;21:289-307.
18. Hruby VJ, Balse PM. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr Med Chem 2000;7:945-970.
19. Bres V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Treand C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M, Benkirane M. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat Cell Biol 2003;5:754-761.
20. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 2002;277:33922-33929.
21. Cho EJ. RNA polymerase II carboxy-terminal domain with multiple connections. Exp Mol Med 2007;39:247-254.
22. Ammosova T, Berro R, Jerebtsova M, Jackson A, Charles S, Klase Z, Southerland W, Gordeuk VR, Kashanchi F, Nekhai S. Phosphoryla- tion of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 2006;3:78.
23. Chun RF, Jeang KT. Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1. J Biol Chem 1996;271:27888-27894.
24. Zhou M, Halanski MA, Radonovich MF, Kashanchi F, Peng J, Price DH, Brady JN. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol 2000;20:5077-5086.